Olema Pharmaceuticals (OLMA) Stock
Small cap biotech company developing novel medicines. Here's the price, business snapshot, and what's worth knowing about Olema Pharmaceuticals in July 2026.
Olema Pharmaceuticals Inc (ticker: OLMA) is a small-cap biopharmaceutical company (market cap about $568.3m) focused on developing and commercialising novel therapeutics. For investors, key considerations include the company’s development pipeline, clinical-trial milestones and regulatory progress — events that can cause significant share-price swings. Smaller biotech firms often have limited revenues and may rely on partnerships, licensing deals or capital raises to fund R&D. That creates upside potential if trials succeed but also heightens risk if results disappoint or financing terms are unfavourable. Liquidity can be lower than for larger stocks, which can increase volatility. Investors should review recent company filings, understand the stage and size of the pipeline, and factor in broader sector dynamics and regulatory trends. This summary is for educational purposes only and not personalised investment advice; seek professional guidance to assess whether OLMA fits your objectives and risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying OLEMA's stock, with a target price suggesting significant growth potential.
Financial Health
OLEMA Pharmaceuticals is showing strong cash flow and solid book value, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring OLMA
Pharma Buyouts Explained | Healthcare M&A Analysis
Merck's decision to end its acquisition talks with Revolution Medicines highlights the high-stakes environment for biotech M&A. This failed deal could signal an opportunity for other pharmaceutical giants to acquire promising oncology assets, creating a ripple effect across the sector.
Published: 26 January 2026
Explore BasketNew Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: 3 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Milestones
Clinical-trial readouts and regulatory steps can materially move the stock, though outcomes are uncertain and can increase volatility.
Financing & Partnerships
Funding rounds and licensing deals often shape the company’s runway and valuation, but may dilute shareholders or change strategy.
Sector Dynamics
Regulatory trends and competitive landscape in pharmaceuticals influence prospects; broader market sentiment also affects smaller-cap stocks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
